#1 Clinical Trials Search in Europe

Metformin

This article examines the use of Metformin, a widely prescribed medication for type 2 diabetes, in various clinical trials. These studies aim to evaluate Metformin’s effectiveness, safety, and potential applications beyond diabetes management. We’ll explore different formulations, dosages, and combinations with other drugs, as well as its impact on patient adherence and bioequivalence studies.

Table of Contents

What is Metformin?

Metformin is a widely used medication that belongs to a class of drugs called biguanides. It is primarily known for its role in treating type 2 diabetes, but research has shown its potential in treating various other conditions. Metformin is also known by other names such as Glucophage, Glumetza, and Riomet[7].

Uses of Metformin

Metformin is used to treat several health conditions:

  • Type 2 Diabetes: This is the primary use of metformin. It helps control blood sugar levels in people with type 2 diabetes[5].
  • Polycystic Ovary Syndrome (PCOS): Metformin can help regulate menstrual irregularities and reduce excessive male hormones (hyperandrogenism) in women with PCOS[1].
  • Metabolic Syndrome: Metformin is being studied for its potential to prevent age-related chronic diseases in people with metabolic syndrome[2].
  • Cancer: Some studies are exploring metformin’s potential in treating certain types of cancer, such as lung cancer[3].
  • Neuroendocrine Tumors: Metformin is being investigated in combination with other drugs for treating advanced neuroendocrine tumors[4].
  • Melasma: This is a skin condition causing dark patches on the face. Some research is looking into metformin’s potential in treating melasma[6].
  • Atrial Fibrillation: Studies are examining whether metformin can help reduce complications in patients with this heart rhythm disorder[7].

How Metformin Works

Metformin works in several ways to improve health:

  • It reduces the amount of glucose (sugar) produced by the liver[5].
  • It increases the sensitivity of body tissues to insulin, helping cells use glucose more effectively[1].
  • It may have anti-inflammatory and antioxidant effects, which could explain its potential benefits in conditions like cancer and heart disease[3][7].
  • In PCOS, it can help reduce insulin resistance, which is often associated with this condition[1].

Dosage and Administration

Metformin is typically taken orally as a tablet. The dosage can vary depending on the condition being treated and the individual patient’s needs. Here are some general guidelines:

  • For diabetes: The usual starting dose is 500 mg or 850 mg twice daily. This can be increased gradually if needed, up to a maximum of 2550 mg per day[2].
  • For other conditions: Dosages may vary. For example, in some studies on atrial fibrillation, a dose of 850 mg once daily is being used[7].
  • Metformin is usually taken with meals to reduce stomach upset[7].

Always follow your doctor’s instructions regarding dosage and administration.

Potential Side Effects

Like all medications, metformin can cause side effects. Common side effects include:

  • Gastrointestinal symptoms such as nausea, diarrhea, and stomach upset[7]
  • Decreased vitamin B12 levels with long-term use
  • Rarely, a serious condition called lactic acidosis, especially in people with kidney problems[7]

It’s important to discuss any side effects with your healthcare provider.

Ongoing Research

Metformin continues to be the subject of extensive research for its potential benefits beyond diabetes treatment. Some areas of ongoing research include:

  • Its potential to extend lifespan and improve overall health in aging populations[2]
  • Its possible role in cancer prevention and treatment[3]
  • Its effects on heart health, particularly in conditions like atrial fibrillation[7]
  • Its potential in treating skin conditions like melasma[6]

As research continues, we may discover even more uses for this versatile medication.

Aspect Details
Primary uses Type 2 diabetes treatment, potential benefits for obesity and insulin resistance
Formulations studied Immediate-release tablets, extended-release (XR) tablets, powder for oral solution
Dosages Varying, including 500mg, 750mg, 850mg, and 1000mg strengths
Combination studies Metformin with Lobeglitazone for type 2 diabetes
Key outcomes measured Blood sugar levels, BMI changes, patient adherence, pharmacokinetic parameters, adverse events
Bioequivalence focus Comparing generic Metformin to brand-name versions like Glucophage
Special populations Studies in healthy volunteers, type 2 diabetes patients, obese adolescents

FAQ

  • What is Metformin used for in clinical trials? Metformin is primarily used in clinical trials for treating type 2 diabetes. However, some studies also explore its potential benefits for other conditions, such as obesity and insulin resistance in patients with chronic hepatitis C.
  • Are there different formulations of Metformin being studied? Yes, clinical trials are investigating various formulations of Metformin, including immediate-release tablets, extended-release (XR) tablets, and powder for oral solution in sachets. These different forms are being studied to assess their effectiveness and patient adherence.
  • What is bioequivalence, and why is it important in Metformin studies? Bioequivalence refers to the comparison of different formulations or brands of a drug to ensure they have the same effect in the body. Several studies focus on bioequivalence to ensure that generic versions of Metformin are as effective as brand-name versions like Glucophage.
  • Are there any studies combining Metformin with other medications? Yes, some clinical trials are investigating the combination of Metformin with other drugs. For example, one study looks at a combination of Metformin and Lobeglitazone for treating type 2 diabetes.
  • What are some of the outcomes measured in Metformin clinical trials? Clinical trials for Metformin measure various outcomes, including changes in blood sugar levels, body mass index (BMI), patient adherence to treatment, pharmacokinetic parameters (like maximum plasma concentration and area under the curve), and the occurrence of adverse events.

Ongoing Clinical Trials on Metformin

  • Evaluating Once Daily Orforglipron (LY3502970) Compared to Insulin Glargine in Adults with Type 2 Diabetes and Obesity or Overweight who Have Increased Cardiovascular Risk

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Austria Czechia Germany Greece Italy Romania +2

  • Study Comparing Orforglipron and Dapagliflozin for Adults with Type 2 Diabetes and Poor Blood Sugar Control on Metformin

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Germany Poland

  • A study comparing cagrilintide and semaglutide combination to semaglutide, cagrilintide, and placebo in adults with type 2 diabetes on metformin

    Not recruiting

    3 1 1
    Investigated Diseases:
    Investigated Drugs:
    Bulgaria Croatia Czechia Denmark Finland Germany +9

  • Study on the Effects of Spironolactone, Pioglitazone, and Metformin for Adolescent Girls and Young Women with Polycystic Ovary Syndrome (PCOS)

    Not recruiting

    2 1
    Investigated Diseases:
    Investigated Drugs:
    Austria Denmark Italy Norway Spain

  • Study of Orforglipron for Adults with Type 2 Diabetes and Poor Blood Sugar Control on Insulin Glargine, with or without Metformin and/or SGLT-2 Inhibitor

    Not recruiting

    3 1 1
    Investigated Diseases:
    Investigated Drugs:
    Romania

  • Study on the Effectiveness and Safety of Gliclazide MR, Dapagliflozin, and Metformin for Patients with Type 2 Diabetes Not Well Controlled with Dapagliflozin

    Not recruiting

    3 1 1
    Investigated Diseases:
    Investigated Drugs:
    Bulgaria Hungary Latvia Lithuania Poland

  • Study on the Effectiveness of Weekly IcoSema (Insulin Icodec and Semaglutide) vs. Daily Insulin Glargine for Adults with Type 2 Diabetes Not Controlled by Oral Drugs

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    Greece Italy Poland

  • Study on Metformin Transfer into Breast Milk and Infant Plasma in Breastfeeding Women with Type 2 or Gestational Diabetes

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    Sweden

  • Comparing inavolisib plus fulvestrant versus alpelisib plus fulvestrant in patients with advanced hormone receptor-positive, HER2-negative breast cancer with PIK3CA mutation

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Belgium France Germany Italy Poland Spain

  • Study on Slowing Advanced Puberty in Girls Using Metformin, Pioglitazone, and Spironolactone

    Not recruiting

    2 1
    Investigated Diseases:
    Investigated Drugs:
    Spain

Glossary

  • Metformin: An oral medication used to treat type 2 diabetes by improving insulin sensitivity and reducing blood sugar levels. It's also known by brand names such as Glucophage.
  • Bioequivalence: A comparison of different formulations or brands of a drug to ensure they have the same effect in the body. This is important for ensuring generic versions of a drug are as effective as brand-name versions.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion. This helps determine proper dosing and effectiveness.
  • Extended-release (XR): A formulation of a medication designed to release the active ingredient slowly over time, allowing for less frequent dosing and potentially fewer side effects.
  • Insulin resistance: A condition where the body's cells don't respond effectively to insulin, leading to high blood sugar levels. This is a key factor in type 2 diabetes.
  • Body Mass Index (BMI): A measure of body fat based on height and weight. It's often used to assess obesity and overall health risks.
  • Adherence: The extent to which a patient follows their prescribed treatment plan, including taking medications as directed.
  • Adverse event: Any unfavorable and unintended sign, symptom, or disease that occurs during a clinical trial, whether or not it's related to the treatment being studied.

References

  1. https://clinicaltrials.gov/study/NCT03757923
  2. https://clinicaltrials.gov/study/NCT02960711
  3. https://clinicaltrials.gov/study/NCT01997775
  4. https://clinicaltrials.gov/study/NCT02823691
  5. https://clinicaltrials.gov/study/NCT01871415
  6. https://clinicaltrials.gov/study/NCT03475524
  7. https://clinicaltrials.gov/study/NCT05878535